Suchergebnisse - Saremi, Aramesh

Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT) von Saremi, Aramesh, Bahn, Gideon, Reaven, Peter D.

Volltext Volltext Volltext

A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT) von Saremi, Aramesh, Bahn, Gideon D., Reaven, Peter D.

Volltext Volltext Volltext

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial von Giorgino, Francesco, Shaunik, Alka, Liu, Minzhi, Saremi, Aramesh

Volltext Volltext Volltext

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) von Koska, Juraj, Saremi, Aramesh, Bahn, Gideon, Yamashita, Shizuya, Reaven, Peter D.

Volltext Volltext Volltext

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration... von Gautier, Thibault, Silwal, Rupesh, Saremi, Aramesh, Boss, Anders, Breton, Marc D.

Volltext Volltext Volltext

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L von Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Volltext Volltext Volltext

Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L von Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.

Volltext Volltext Volltext

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L von Blonde, Lawrence, Berard, Lori, Saremi, Aramesh, Huang, Yao, Aroda, Vanita R., Raccah, Denis

Volltext Volltext Volltext

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial von Saremi, Aramesh, Schwenke, Dawn C., Bahn, Gideon, Ge, Ling, Emanuele, Nicholas, Reaven, Peter D.

Volltext Volltext Volltext

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study von Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C., Bahn, Gideon, Beisswenger, Paul J., Reaven, Peter D.

Volltext Volltext Volltext

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study von Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco

Volltext Volltext Volltext

Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT) von Saremi, Aramesh, Moritz, Thomas E., Anderson, Robert J., Abraira, Carlos, Duckworth, William C., Reaven, Peter D.

Volltext Volltext Volltext

Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance von Hu, Xia, Reaven, Peter D., Saremi, Aramesh, Liu, Ninghao, Abbasi, Mohammad Ali, Liu, Huan, Migrino, Raymond Q.

Volltext Volltext Volltext

Association Between IL-6 and the extent of Coronary Atherosclerosis in The Veterans Affairs Diabetes Trial (VADT) von Saremi, Aramesh, Anderson, Robert J., Luo, Ping, Moritz, Thomas E., Schwenke, Dawn C., Allison, Mathew, Reaven, Peter D.

Volltext Volltext Volltext

Quantification of LVEF≤35% misclassification by 2D-echocardiography as compared to cardiac magnetic resonance in coronary artery disease: implications for AICD therapy von Parrington, Diane J, Saremi, Aramesh, Girotra, Sudhakar V, Dev, Sandesh, Oh, Charles, Scott, Cynthia L, Migrino, Raymond Q

Volltext Volltext

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes von Koska, Juraj, Saremi, Aramesh, Howell, Scott, Bahn, Gideon, De Courten, Barbora, Ginsberg, Henry, Beisswenger, Paul J., Reaven, Peter D.

Volltext Volltext Volltext

Hepatic Fat and Inflammation in Type 2 Diabetes von Saremi, Aramesh, Allison, Matthew, Ditomasso, Dominic, Ge, Ling, Anderson, Robert, Moritz, Tom E., Duckworth, William, Abraira, Carlos, Reaven, Peter D.

Volltext Volltext Volltext

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score... von Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.

Volltext Volltext Volltext

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Explorat... von Del Prato, Stefano, Frias, Juan Pablo, Blonde, Lawrence, Aroda, Vanita R., Shehadeh, Niam, Saremi, Aramesh, Dex, Terry, Niemoeller, Elisabeth, Souhami, Elisabeth, Liu, Minzhi, Rosenstock, Julio

Volltext Volltext Volltext

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors von Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.

Volltext Volltext Volltext